Skip to main content

Advertisement

SpringerLink
Log in

Hepatitis B virus-induced hepatocellular carcinoma: a persistent global problem

  • Bacterial, Fungal and Virus Molecular Biology - Review
  • Published:
Brazilian Journal of Microbiology Aims and scope Submit manuscript

Abstract

Hepatitis B virus (HBV) infections are highly prevalent globally, representing a serious public health problem. The diverse modes of transmission and the burden of the chronic carrier population pose challenges to the effective management of HBV. Vaccination is the most effective preventive measure available in the current scenario. Still, HBV is one of the significant health issues in various parts of the globe due to non-response to vaccines, the high number of concealed carriers, and the lack of access and awareness. Universal vaccination programs must be scaled up in neonates, especially in the developing parts of the world, to prevent new HBV infections. Novel treatments like combinational therapy, gene silencing, and new antivirals must be available for effective management. The prolonged infection of HBV, direct and indirect, can promote the growth of hepatocellular carcinoma (HCC). The present review emphasizes the problems and probable solutions for better managing HBV infections, causal risk factors of HCC, and mechanisms of HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

Not applicable.

References

  1. WHO (2019) Hepatitis. https://www.who.int/news-room/questions-and-answers/item/hepatitis. Accessed 10 Oct 2022

  2. WHO (2022) Hepatitis-b. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b Accessed 10 Oct 2022

  3. Hoofnagle JH, Di Bisceglie AM (1991) Serologic diagnosis of acute and chronic viral hepatitis. In: Seminars in liver disease, vol 11, no. 02. Thieme Medical Publishers, Inc, pp 73–83

  4. El-Serag HB (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142(6):1264–1273

    Article  PubMed  Google Scholar 

  5. Liang TJ (2009) Hepatitis B: the virus and disease. Hepatology 49(S5):S13–S21

    Article  CAS  PubMed  Google Scholar 

  6. Aspinall EJ, Hawkins G, Fraser A et al (2011) Hepatitis B prevention, diagnosis, treatment and care: a review. Occup Med 61(8):531–540

    Article  CAS  Google Scholar 

  7. Kayaaslan B, Guner R (2017) Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol 9(5):227

    Article  PubMed  PubMed Central  Google Scholar 

  8. Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11(2):97–107

    Article  CAS  PubMed  Google Scholar 

  9. Trépo C, Chan HL, Lok A (2014) Hepatitis B virus infection. The Lancet 384(9959):2053–2063

    Article  Google Scholar 

  10. Meireles LC, Marinho RT, Van Damme P (2015) Three decades of hepatitis B control with vaccination. World J Hepatol 7(18):2127

    Article  PubMed  PubMed Central  Google Scholar 

  11. Wang J, Huang H, Liu Y, Chen R et al (2020) HBV genome and life cycle. In: Tang H (eds) Hepatitis B Virus Infection. Advances in experimental medicine and biology, vol 1179. Springer, Singapore, pp 17–37. https://doi.org/10.1007/978-981-13-9151-4_2

  12. Herrscher C, Roingeard P, Blanchard E (2020) Hepatitis B virus entry into cells. Cells 9(6):1486

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hayes CN, Zhang Y, Makokha GN et al (2016) Early events in hepatitis B virus infection: from the cell surface to the nucleus. J Gastroenterol Hepatol 31(2):302–309

    Article  CAS  PubMed  Google Scholar 

  14. Huang HC, Chen CC, Chang WC et al (2012) Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis. Virol J 86(17):9443–9453

    Article  CAS  Google Scholar 

  15. Li W (2015) The hepatitis B virus receptor. Annu Rev Cell Dev Biol 31:125–147

    Article  CAS  PubMed  Google Scholar 

  16. Yan H, Zhong G, Xu G et al (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1:e00049

  17. Salhab A, Amer J, Safadi R (2018) Sodium taurocholate co-transporting polypeptide (NTCP) as novel checkpoint in NK cells activity in liver fibrosis. In: Hepatology, vol 68, pp 647A-648A. Wiley, Hoboken, pp 07030–5774

  18. Bowden S, Jackson K, Littlejohn M, Locarnini S (2004) Quantification of HBV covalently closed circular DNA from liver tissue by Real-Time PCR. In: Hamatake RK, Lau JYN (eds) Hepatitis B and D Protocols. Methods in Molecular Medicine, vol 95. Humana Press, pp 41–50. https://doi.org/10.1385/1-59259-669-X:41

  19. Tang H, McLachlan A (2001) Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. PNAS 98(4):1841–1846

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Urban S, Schulze A, Dandri M, Petersen J (2010) The replication cycle of hepatitis B virus. J Hepatol 52(2):282–284

    Article  PubMed  Google Scholar 

  21. Lucifora J, Arzberger S, Durantel D et al (2011) Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 55(5):996–1003

    Article  CAS  PubMed  Google Scholar 

  22. Nassal M (2008) Hepatitis B viruses: reverse transcription a different way. Virus Res 134(1–2):235–249

    Article  CAS  PubMed  Google Scholar 

  23. Jones SA, Hu J (2013) Hepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral intervention. Emerg Microbes Infect 2(1):1–11

    Article  Google Scholar 

  24. Dandri M, Petersen J (2016) Mechanism of hepatitis B virus persistence in hepatocytes and its carcinogenic potential. Clin Infect Dis 62(suppl_4):S281–S288

  25. Inoue T, Tanaka Y (2016) Hepatitis B virus and its sexually transmitted infection-an update. Microbial Cell 3(9):420

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Mariano A, Mele A, Tosti ME et al (2004) Role of beauty treatment in the spread of parenterally transmitted hepatitis viruses in Italy. J Med Virol 74(2):216–220

    Article  PubMed  Google Scholar 

  27. Hui PW, Ng C, Cheung KW, Lai CL (2020) Acceptance of antiviral treatment and enhanced service model for pregnant patients carrying hepatitis B. Hong Kong Med J 26(4):318

    CAS  PubMed  Google Scholar 

  28. Scott RM, Snitbhan R, Bancroft WH et al (1980) Experimental transmission of hepatitis B virus by semen and saliva. J Infect Dis 142(1):67–71

    Article  CAS  PubMed  Google Scholar 

  29. Karayiannis P, Novick DM, Lok AS et al (1985) Hepatitis B virus DNA in saliva, urine, and seminal fluid of carriers of hepatitis B e antigen. Br Med J (Clin Res Ed) 290(6485):1853–1855

    Article  CAS  PubMed  Google Scholar 

  30. Hebo HJ, Gemeda DH, Abdusemed KA (2019) Hepatitis B and C viral infection: prevalence, knowledge, attitude, practice, and occupational exposure among healthcare workers of Jimma University Medical Center, southwest Ethiopia. Sci World J. https://doi.org/10.1155/2019/9482607

    Article  Google Scholar 

  31. Roien R, Mousavi SH, Ozaki A et al (2021) Assessment of knowledge, attitude, and practice of health-care workers towards hepatitis B virus prevention in Kabul, Afghanistan. JMDH 14:3177

    Article  PubMed  PubMed Central  Google Scholar 

  32. Coppola N, De Pascalis S, Onorato L et al (2016) Hepatitis B virus and hepatitis C virus infection in healthcare workers. World J Hepatol 8(5):273

    Article  PubMed  PubMed Central  Google Scholar 

  33. Hou J, Liu Z, Gu F (2005) Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci 2(1):50

    Article  PubMed  PubMed Central  Google Scholar 

  34. Aljarbou AN (2013) The Emergent Concern of Hepatitis B globally with special attention to Kingdom of Saudi Arabia. Int J Health Sci 7(3):333

    Google Scholar 

  35. Russi JC, Serra M, Viñoles J et al (2003) Sexual transmission of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1 infections among male transvestite comercial sex workers in Montevideo, Uruguay. Am J Trop Med 68(6):716–720

    Article  Google Scholar 

  36. Van Houdt R, Bruisten SM, Geskus RB et al (2010) Ongoing transmission of a single hepatitis B virus strain among men having sex with men in Amsterdam. J Viral Hepat 17(2):108–114

    Article  PubMed  Google Scholar 

  37. Chilaka VN, Konje JC (2021) Viral hepatitis in pregnancy. Eur J Obstet Gynecol 256:287–296

    Article  Google Scholar 

  38. Beasley RP, Trepo C, Stevens CE, Szmuness W (1977) The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 105(2):94–98

    Article  CAS  PubMed  Google Scholar 

  39. Hyams KC (1995) Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 20(4):992–1000

    Article  CAS  PubMed  Google Scholar 

  40. Schweitzer A, Horn J, Mikolajczyk RT et al (2015) Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. The Lancet 386(10003):1546–1555

    Article  Google Scholar 

  41. Custer B, Sullivan SD, Hazlet TK et al (2004) Global epidemiology of hepatitis B. virus J Clin Gastroenterol 38(10):S158–S168

  42. Shepard CW, Simard EP, Finelli L et al (2006) Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 28(1):112–125

    Article  PubMed  Google Scholar 

  43. Yan YP, Su HX, Ji Z et al (2014) Epidemiology of hepatitis B virus infection in China: current status and challenges. J Clin Transl Hepatol 2(1):15

    PubMed  PubMed Central  Google Scholar 

  44. Razavi-Shearer D, Gamkrelidze I, Nguyen MH et al (2018) Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 3(6):383–403

    Article  Google Scholar 

  45. Mahoney FJ (1999) Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 12(2):351–366

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Puri P (2014) Tackling the hepatitis B disease burden in India. JCEH 4(4):312–319

    PubMed  PubMed Central  Google Scholar 

  47. Ott JJ, Stevens GA, Groeger J, Wiersma (2012) Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30(12):2212–2219

    Article  CAS  PubMed  Google Scholar 

  48. Khosravani A, Sarkari B, Negahban H et al (2012) Hepatitis B Infection among high risk population: a seroepidemiological survey in Southwest of Iran. BMC infec dis 12(1):1–4

    Article  Google Scholar 

  49. Ozer A, Yakupogullari Y, Beytur A et al (2011) Risk factors of hepatitis B virus infection in Turkey: a population-based, case-control study: risk factors for HBV infection. Hepat Mon 11(4):263

    PubMed  PubMed Central  Google Scholar 

  50. Chu CM, Liaw YF (2016) Natural history of hepatitis B virus infection. In: Hepatitis B virus in human diseases. Humana Press, Cham, pp 217–247

  51. Lok AS, McMahon BJ (2007) Chronic hepatitis B. Hepatology-Baltimore then Orlando- 45(2):507

    Article  CAS  Google Scholar 

  52. Mandalà M, Fagiuoli S, Francisci D et al (2013) Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis. Crit Rev Oncol 87(1):12–27

    Article  Google Scholar 

  53. Nishikawa H, Osaki Y (2015) Liver cirrhosis: evaluation, nutritional status, and prognosis. Mediators Inflamm 2015. https://doi.org/10.1155/2015/872152

  54. Ellis EL, Mann DA (2012) Clinical evidence for the regression of liver fibrosis. J Hepatol 56(5):1171–1180

    Article  PubMed  Google Scholar 

  55. Fattovich G (2003) Natural history of hepatitis B. J Hepatol 39:50–58

    Article  Google Scholar 

  56. Wu J, Ge L, Lu L (2022) Letter to the editor on “Perfluorobutane contrast-enhanced ultrasonography for the diagnosis of HCC: a systematic review and meta-analysis”. Abdom Radiol 1:1–2

    Google Scholar 

  57. Pan YX, Sun XQ, Hu ZL et al (2021) Prognostic values of alpha-fetoprotein and des-gamma-carboxyprothrombin in hepatocellular carcinoma in China: An analysis of 4792 patients. J Hepatocell 25:657–670

    Article  Google Scholar 

  58. King MJ, Laothamatas I, Reddy A, Wax R, Lewis S (2022) Cross-sectional imaging findings of atypical liver malignancies and diagnostic pitfalls: emphasis on computed tomography, and magnetic resonance imaging. Radiologic Clinics 60(5):775–794

    PubMed  Google Scholar 

  59. Liu R, Li Y, Wu A et al (2021) Identification of plasma hsa_circ_0005397 and combined with serum AFP, AFP-L3 as potential biomarkers for hepatocellular carcinoma. Front pharmacol 12:639963

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Caviglia GP, Ciruolo M, Abate ML et al (2020) Alpha-fetoprotein, protein induced by vitamin K absence or antagonist II and glypican-3 for the detection and prediction of hepatocellular carcinoma in patients with cirrhosis of viral etiology. Cancers 12(11):3218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Ali OM, El Amin HA, Sharkawy YL et al (2020) Golgi protein 73 versus alpha-fetoprotein as a new biomarker in early diagnosis of hepatocellular carcinoma. Int J Gen Med 18:193–200

    Article  Google Scholar 

  62. Bruha R, Vitek L, Smid V (2020) Osteopontin–A potential biomarker of advanced liver disease. Ann Hepatol 19(4):344–352

    Article  CAS  PubMed  Google Scholar 

  63. Suda T, Yamashita T, Sunagozaka H et al (2022) (2022) Dickkopf-1 promotes angiogenesis and is a biomarker for hepatic stem cell-like hepatocellular carcinoma. Int J Biol Sci 23(5):2801

    CAS  Google Scholar 

  64. Wu X, Li J, Gassa A et al (2020) Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma. Int J Biol Sci 16(9):1551

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Osasona OG, Oguntoye T, Eromon P et al (2023) Atypical serologic profiles of hepatitis B virus infection across clinical cohorts of patients in Southwestern Nigeria. J Immunoass Immunochem 44(2):176–191

    Article  CAS  Google Scholar 

  66. Zangiabadian M, Zamani A, Nasiri MJ, Behzadi E, Fooladi AA (2022) Diagnostic accuracy and validity of serological and molecular tests for hepatitis B and C. Curr Pharm Biotechnol 23(6):803–817

    Article  CAS  PubMed  Google Scholar 

  67. Pas SD, Tran N, de Man RA, Burghoorn-Maas C, Vernet G, Niesters HG (2008) Comparison of reverse hybridization, microarray, and sequence analysis for genotyping hepatitis B virus. J Clin Microbiol 46(4):1268–1273

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Liang J, Liang X, Ma H, Nie L, Tian Y, Chen G, Wang Y (2021) Detection of hepatitis B virus M204V mutation quantitatively via real-time PCR. J Clin Transl Hepatol 9(2):143

    PubMed  PubMed Central  Google Scholar 

  69. Chen X, Wang S, Tan Y, Huang J, Yang X, Li S (2021) Nanoparticle-based lateral flow biosensors integrated with loop-mediated isothermal amplification for the rapid and visual diagnosis of hepatitis B virus in clinical application. Front Bioeng Biotechnol 9:731415

    Article  PubMed  PubMed Central  Google Scholar 

  70. Takano S, Yokosuka O, Imazeki F et al (1995) Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatol 21(3):650–655

    Article  CAS  Google Scholar 

  71. Chu CM (2000) Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 15:E25–E30

    Article  PubMed  Google Scholar 

  72. Liu F, Wang XW, Chen L et al (2016) Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance. Aliment Pharmacol Ther 43(12):1253–1261

    Article  CAS  PubMed  Google Scholar 

  73. Ozakyol A (2017) Global epidemiology of hepatocellular carcinoma (HCC epidemiology). JGO 48(3):238–240

    Google Scholar 

  74. Yip TCF, Wong GLH, Chan HLY et al (2020) Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus. J Gastroenterol Hepatol 35(12):2210–2219

    Article  CAS  PubMed  Google Scholar 

  75. Bashir Hamidu R, Chalikonda DM, Hann HW (2021) Gender disparity in host responses to hepatitis B-related hepatocellular carcinoma: a case series. Vaccines 9(8):838

    Article  PubMed  PubMed Central  Google Scholar 

  76. Blonski W, Kotlyar DS, Forde KA (2010) Non-viral causes of hepatocellular carcinoma. World J Gastroenterol 16(29):3603

    Article  PubMed  PubMed Central  Google Scholar 

  77. McGlynn KA, London WT (2005) Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 19(1):3–23

    Article  PubMed  Google Scholar 

  78. Yang JD, Hainaut P, Gores GJ, Amadou A et al (2019) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16(10):589–604

    Article  PubMed  PubMed Central  Google Scholar 

  79. Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118(12):3030–3044

    Article  CAS  PubMed  Google Scholar 

  80. Kale A (2021) Hepatocellular carcinoma: diagnosis and surveillance. Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach. IntechOpen. https://doi.org/10.5772/intechopen.99839

  81. Maor Y, Malnick S (2013) Liver injury induced by anticancer chemotherapy and radiation therapy. Int J Hepatol. https://doi.org/10.1155/2013/815105

    Article  PubMed  PubMed Central  Google Scholar 

  82. Tarocchi M, Polvani S, Marroncini G, Galli A (2014) Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World J Gastroenterol 20(33):11630

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Wang M, Xi D, Ning Q (2017) Virus-induced hepatocellular carcinoma with special emphasis on HBV. Hepatol Int 11(2):171–180

    Article  PubMed  Google Scholar 

  84. Ortega-Prieto AM, Dorner M (2017) Immune evasion strategies during chronic hepatitis B and C virus infection. Vaccines 5(3):24

    Article  PubMed  PubMed Central  Google Scholar 

  85. Chen CJ, Yang HI, Su JU et al (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1):65–73

    Article  CAS  PubMed  Google Scholar 

  86. Burns GS, Thompson AJ (2014) Viral hepatitis B: clinical and epidemiological characteristics. Cold Spring Harb Perspect Med 4(12):a024935

    Article  PubMed  PubMed Central  Google Scholar 

  87. Xu Q, Gu S, Liang J, Lin Z et al (2019) The biological function of hepatitis B virus X protein in hepatocellular carcinoma. Oncol Res 27(4):509

    Article  PubMed  PubMed Central  Google Scholar 

  88. Ali A, Abdel-Hafiz H, Suhail M, Al-Mars A et al (2014) Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma. World J Gastroenterol 20(30):10238

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Liu S, Koh SS, Lee CG (2016) Hepatitis B virus X protein and hepatocarcinogenesis. Int J Mol Sci 17(6):940

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Ogunwobi OO, Harricharran T, Huaman et al (2019) Mechanisms of hepatocellular carcinoma progression. World J Gastroenterol 25(19):2279

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Mahoney, FJ, Kane M (1999) Hepatitis B vaccine in: vaccines. Plotkin, SA, Orenstein, WA

  92. Durantel D, Zoulim F (2016) New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol 64(1):S117–S131

    Article  CAS  PubMed  Google Scholar 

  93. Gane EJ (2017) Future anti-HBV strategies. Liver Int 37:40–44

    Article  CAS  PubMed  Google Scholar 

  94. Fujiwara K, Yokosuka O, Kojima H et al (2005) Importance of adequate immunosuppressive therapy for the recovery of patients with “life-threatening” severe exacerbation of chronic hepatitis B. World J Gastroenterol 11(8):1109–1114

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Rijckborst V, Janssen HL (2010) The role of interferon in hepatitis B therapy. Curr Hepat Rep 9(4):231–238

    Article  PubMed  PubMed Central  Google Scholar 

  96. Clercq ED, Férir G, Kaptein S, Neyts J (2010) Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses 2(6):1279–1305

    Article  PubMed  PubMed Central  Google Scholar 

  97. Szmuness W, Stevens CE, Zang EA et al (1981) A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1(5):377–385

    Article  CAS  PubMed  Google Scholar 

  98. McAleer WJ, Buynak EB, Maigetter RZ et al (1992) Human hepatitis B vaccine from recombinant yeast. 1984. Biotechnology (Reading, Mass.) 24:500–502

  99. Vitaliti G, Praticò AD, Cimino C et al (2013) Hepatitis B vaccine in celiac disease: yesterday, today and tomorrow. World J Gastroenterol 19(6):838

    Article  PubMed  PubMed Central  Google Scholar 

  100. Averhoff F, Mahoney F, Coleman P et al (1998) Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 15(1):1–8

    Article  CAS  PubMed  Google Scholar 

  101. Geier MR, Geier DA, Zahalsky AC (2003) A review of hepatitis B vaccination. Expert Opin Drug Saf 2(2):113–122

    Article  PubMed  Google Scholar 

  102. Zanetti AR, Mariano A, Romanò L et al (2005) Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 366(9494):1379–1384

    Article  CAS  PubMed  Google Scholar 

  103. Leuridan E, Van Damme P (2011) Hepatitis B and the need for a booster dose. Clin Infect Dis 53(1):68–75

    Article  PubMed  Google Scholar 

  104. Coates T, Wilson R, Patrick G et al (2001) Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther 23(3):392–403

    Article  CAS  PubMed  Google Scholar 

  105. Walayat S, Ahmed Z, Martin D, Puli S et al (2015) Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine. World J Hepatol 7(24):2503

    Article  PubMed  PubMed Central  Google Scholar 

  106. Roukens AH, Visser LG (2011) Hepatitis B vaccination strategy in vaccine low and non-responders: a matter of quantity of quality? Hum Vaccin 7(6):654–657

    Article  CAS  PubMed  Google Scholar 

  107. Tseng TC, Liu CJ, Chang CT et al (2020) HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis. J Hepatol 72(6):1105–1111

    Article  CAS  PubMed  Google Scholar 

  108. Chen HL, Lin LH, Hu FC et al (2012) Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology 142(4):773–781

    Article  PubMed  Google Scholar 

  109. World Health Organization (2020) Prevention of mother-to-child transmission of hepatitis B virus (HBV): Guidelines on antiviral prophylaxis in pregnancy. World Health Organization

  110. Zangiabadian M, Zamani A, Nasiri MJ et al (2022) Diagnostic accuracy and validity of serological and molecular tests for hepatitis B and C. Curr Pharm Biotechnol 23(6):803–817

    Article  CAS  PubMed  Google Scholar 

  111. Datta S, Chatterjee S, Veer V (2014) Recent advances in molecular diagnostics of hepatitis B virus. World J Gastroenterol 20(40):14615

    Article  PubMed  PubMed Central  Google Scholar 

  112. Sharma V, Kumar D, Dhull D et al (2017) Molecular detection of hepatitis B viruses (HBV). Int Blood Res Rev 7(1):1–6

    Article  Google Scholar 

  113. Forbi JC, Obagu JO, Gyar SD et al (2010) Application of dried blood spot in the sero-diagnosis of hepatitis B infection (HBV) in an HBV hyper-endemic nation. Ann Afr Med 9(1):44

    Article  PubMed  Google Scholar 

  114. Tesfaye T (2020) A mathematical model analysis on the spread and control of chronic and hyper toxic forms of hepatitis b virus in Ethiopia (Doctoral dissertation)

  115. Villar LM, Cruz HM, Barbosa JR et al (2015) Update on hepatitis B and C virus diagnosis. World J Virol 4(4):323

    Article  PubMed  PubMed Central  Google Scholar 

  116. Torbenson M, Thomas DL (2002) Occult hepatitis B. Lancet Infect Dis 2(8):479–486

    Article  PubMed  Google Scholar 

  117. Playford EG, Hogan PG, Bansal AS et al (2002) Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine. Infect Control Hosp Epidemiol 23(2):87–90

    Article  PubMed  Google Scholar 

  118. Leonardi S, Praticò AD, Lionetti E et al (2012) Intramuscular vs intradermal route for hepatitis B booster vaccine in celiac children. WJG 18(40):5729

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Levitz RE, Cooper BW, Regan HC (1995) Immunization with high-dose intradermal recombinant hepatitis B vaccinein healthcare workers who failed to respond to intramuscular vaccination. Infect Control Hosp Epidemiol 16(2):88–91

    Article  CAS  PubMed  Google Scholar 

  120. Chanchairujira T, Chantaphakul N, Thanwandee T, Ong-Ajyooth L (2006) Efficacy of intradermal hepatitis B vaccination compared to intramuscular vaccination in hemodialysis patients. J Med Assoc Thai 89(Suppl 2):S33–S40

    PubMed  Google Scholar 

  121. Ghebrehewet S, Baxter D, Falconer M, Paver K (2008) Intradermal recombinant hepatitis B vaccination (IDRV) for non-responsive healthcare workers (HCWs). Hum Vaccin 4(4):280–285

    Article  CAS  PubMed  Google Scholar 

  122. Barraclough KA, Wiggins KJ, Hawley CM et al (2009) Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. AJKD 54(1):95–103

    Article  PubMed  Google Scholar 

  123. Fabrizi F, Dixit V, Messa P, Martin P (2011) Intradermal vs intramuscular vaccine against hepatitis B infection in dialysis patients: a meta-analysis of randomized trials. J Viral Hepat 18(10):730–737

    Article  CAS  PubMed  Google Scholar 

  124. Whitaker JA, Rouphael NG, Edupuganti S et al (2012) Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis 12(12):966–976

    Article  PubMed  PubMed Central  Google Scholar 

  125. Filippelli M, Lionetti E, Gennaro A et al (2014) Hepatitis B vaccine by intradermal route in non responder patients: an update. WJG 20(30):10383

    Article  PubMed  PubMed Central  Google Scholar 

  126. Bertoletti A, Ferrari C (2012) Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61(12):1754–1764

    Article  CAS  PubMed  Google Scholar 

  127. Guo H, Jiang D, Ma D et al (2009) Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. Virol J 83(2):847–858

    Article  CAS  Google Scholar 

  128. Zhang RN, Pan Q, Zhang Z et al (2015) Saturated fatty acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic Fatty liver disease by toll-like receptor 4-mediated innate immune response. Hepat Mon 15(5):e27909. https://doi.org/10.5812/hepatmon.32636

  129. Embrechts W, Herschke F, Pauwels F, Stoops et al (2018) 2, 4-Diaminoquinazolines as dual toll-like receptor (TLR) 7/8 modulators for the treatment of hepatitis B virus. J Med Chem 61(14):6236–6246

    Article  CAS  PubMed  Google Scholar 

  130. Colpitts CC, Verrier ER, Baumert TF (2015) Targeting viral entry for treatment of hepatitis B and C virus infections. ACS Infect Dis 1(9):420–427

    Article  CAS  PubMed  Google Scholar 

  131. Verrier ER, Colpitts CC, Sureau C et al (2016) Hepatitis B virus receptors and molecular drug targets. Hepatol Int 10(4):567–573

    Article  PubMed  Google Scholar 

  132. Urban S, Bartenschlager R, Kubitz R et al (2014) Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 147(1):48–64

    Article  CAS  PubMed  Google Scholar 

  133. Bhardwaj P, Kant R, Behera SP et al (2022) Next-generation diagnostic with CRISPR/Cas: beyond nucleic acid detection. Int J Mol Sci 23(11):6052

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Kumar N, Sharma S, Kumar R et al (2020) Host-directed antiviral therapy. Clin Microbiol Rev 33(3):e00168-e219

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Karayiannis P (2003) Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother 51(4):761–785

    Article  CAS  PubMed  Google Scholar 

  136. Samani ZN, Kopaei MR (2018) Effective medicinal plants in treating hepatitis B. Int J Pharm Sci 9(9):3589–3596. https://doi.org/10.13040/IJPSR.0975-8232.9(9).3589-96

  137. Siddiqui MH, Alamri SA, Al-Whaibi MH et al (2017) A mini-review of anti-hepatitis B virus activity of medicinal plants. Biotechnol Biotechnol Equip 31(1):9–15

    Article  CAS  Google Scholar 

  138. Xia J, Inagaki Y, Song P et al (2016) Advance in studies on traditional Chinese medicines to treat infection with the hepatitis B virus and hepatitis C virus. Biosci Trends 10(5):327–336

    Article  CAS  PubMed  Google Scholar 

  139. Wei ZQ, Zhang YH, Ke CZ et al (2017) Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation. World J Gastroenterol 23(34):6252

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Wei PH, Wu SZ, Mu XM et al (2015) Effect of alcohol extract of Acanthus ilicifolius L. on anti-duck hepatitis B virus and protection of liver. J Ethnopharmacol 160:1–5

    Article  PubMed  Google Scholar 

  141. Mehrotra R, Rawat S, Kulshreshtha DK et al (1991) In vitro effect of Phyllanthus amarus on hepatitis B virus. IJMR 93:71–73

    CAS  PubMed  Google Scholar 

  142. Kristófi R, Eriksson JW (2021) Metformin as an anti-inflammatory agent: a short review. Int J Endocrinol 251(2):R11–R22

    Article  Google Scholar 

  143. Li B, Guo QL et al (2016) New anti-HBV C-boivinopyranosyl flavones from Alternanthera philoxeroides. Molecules 21(3):336

    Article  PubMed  PubMed Central  Google Scholar 

  144. Cui X, Wang Y, Kokudo N et al (2010) Traditional Chinese medicine and related active compounds against hepatitis B virus infection. Biosci Trends 4(2):39–47

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Biotechnology, Maharshi Dayanand University, 124001, Haryana, Rohtak, India

    Sanjit Boora, Vikrant Sharma & Samander Kaushik

  2. Department of Genetics, Maharshi Dayanand University, Rohtak, India

    Sulochana Kaushik

  3. Regional & Analytical Laboratory, Kovvada, Bhimavaram, A.P, India

    Ajoy Varma Bhupatiraju

  4. Department of Biochemistry, Maharshi Dayanand University, Rohtak, India

    Sandeep Singh

Authors
  1. Sanjit Boora
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vikrant Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sulochana Kaushik
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ajoy Varma Bhupatiraju
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sandeep Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Samander Kaushik
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Sanjit Boora, Vikrant Sharma, and Samander Kaushik have performed the conception or design of the study. Samander Kaushik, Sulochana Kaushik, Ajoy Varma Bhupatiraju, and Sandeep Singh in editing, acquisition, analysis, or interpretation of the data.

Corresponding author

Correspondence to Samander Kaushik.

Ethics declarations

All data relevant to the study is included in the article.

Ethical approval

NA.

Conflict of interest

The authors declare no competing interests.

Additional information

Responsible Editor: Flavio Guimaraes Fonseca

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boora, S., Sharma, V., Kaushik, S. et al. Hepatitis B virus-induced hepatocellular carcinoma: a persistent global problem. Braz J Microbiol 54, 679–689 (2023). https://doi.org/10.1007/s42770-023-00970-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s42770-023-00970-y

Keywords

Search

Navigation